Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
Who this might be right for
Breast Cancer
MacroGenics 25